Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

ESMO Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. eCollection 2019.


A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.

Xu C, Ravva P, Dang JS, Laurent J, Adessi C, McIntyre C, Meneses-Lorente G, Mercier F.

Cancer Chemother Pharmacol. 2018 Sep;82(3):395-406. doi: 10.1007/s00280-018-3621-9. Epub 2018 Jun 18.


Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.

Moisan A, Michielin F, Jacob W, Kronenberg S, Wilson S, Avignon B, Gérard R, Benmansour F, McIntyre C, Meneses-Lorente G, Hasmann M, Schneeweiss A, Weisser M, Adessi C.

Mol Cancer Ther. 2018 Jul;17(7):1464-1474. doi: 10.1158/1535-7163.MCT-17-1268. Epub 2018 Apr 13.


Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.


89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE.

Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21.


Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.


Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.

Meneses-Lorente G, McIntyre C, Hsu JC, Thomas M, Jacob W, Adessi C, Weisser M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1239-1247. doi: 10.1007/s00280-017-3328-3. Epub 2017 May 11.


First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.


Conductance, surface traps, and passivation in doped silicon nanowires.

Fernandez-Serra MV, Adessi Ch, Blase X.

Nano Lett. 2006 Dec;6(12):2674-8.


Surface segregation and backscattering in doped silicon nanowires.

Fernández-Serra MV, Adessi Ch, Blase X.

Phys Rev Lett. 2006 Apr 28;96(16):166805. Epub 2006 Apr 27.


A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers.

Wellnitz S, Friedlein A, Bonanni C, Anquez V, Goepfert F, Loetscher H, Adessi C, Czech C.

J Neurochem. 2005 Sep;94(5):1351-60. Epub 2005 Jul 11.


Role of the dopant in the superconductivity of diamond.

Blase X, Adessi Ch, Connétable D.

Phys Rev Lett. 2004 Dec 3;93(23):237004. Epub 2004 Nov 30.


Passage of murine scrapie prion protein across the mouse vascular blood-brain barrier.

Banks WA, Niehoff ML, Adessi C, Soto C.

Biochem Biophys Res Commun. 2004 May 21;318(1):125-30.


Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease.

Adessi C, Frossard MJ, Boissard C, Fraga S, Bieler S, Ruckle T, Vilbois F, Robinson SM, Mutter M, Banks WA, Soto C.

J Biol Chem. 2003 Apr 18;278(16):13905-11. Epub 2003 Feb 10.


Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease?

Permanne B, Adessi C, Fraga S, Frossard MJ, Saborio GP, Soto C.

J Neural Transm Suppl. 2002;(62):293-301. Review.


Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide.

Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, Soto C.

FASEB J. 2002 Jun;16(8):860-2. Epub 2002 Apr 10.


Converting a peptide into a drug: strategies to improve stability and bioavailability.

Adessi C, Soto C.

Curr Med Chem. 2002 May;9(9):963-78. Review.


Discernibility criterion in Fresnel projection microscopy.

Adessi CA, Devel M.

J Electron Microsc (Tokyo). 2001;50(2):97-100.


Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms.

Adessi C, Matton G, Ayala G, Turcatti G, Mermod JJ, Mayer P, Kawashima E.

Nucleic Acids Res. 2000 Oct 15;28(20):E87.


Characterization of Dictyostelium discoideum cathepsin D.

Journet A, Chapel A, Jehan S, Adessi C, Freeze H, Klein G, Garin J.

J Cell Sci. 1999 Nov;112 ( Pt 21):3833-43.


Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients.

Rabilloud T, Adessi C, Giraudel A, Lunardi J.

Electrophoresis. 1997 Mar-Apr;18(3-4):307-16.


The cysteine proteinase gene cprG in Dictyostelium discoideum has a serine-rich domain that contains GlcNAc-1-P.

Ord T, Adessi C, Wang L, Freeze HH.

Arch Biochem Biophys. 1997 Mar 1;339(1):64-72.


Two-dimensional electrophoresis of membrane proteins: a current challenge for immobilized pH gradients.

Adessi C, Miege C, Albrieux C, Rabilloud T.

Electrophoresis. 1997 Jan;18(1):127-35.


Identification of major proteins associated with Dictyostelium discoideum endocytic vesicles.

Adessi C, Chapel A, Vinçon M, Rabilloud T, Klein G, Satre M, Garin J.

J Cell Sci. 1995 Oct;108 ( Pt 10):3331-7.

Supplemental Content

Loading ...
Support Center